Cargando…

Ten years in the making: application of CrossMab technology for the development of therapeutic bispecific antibodies and antibody fusion proteins

Bispecific antibodies have recently attracted intense interest. CrossMab technology was described in 2011 as novel approach enabling correct antibody light-chain association with their respective heavy chain in bispecific antibodies, together with methods enabling correct heavy-chain association usi...

Descripción completa

Detalles Bibliográficos
Autores principales: Surowka, Marlena, Schaefer, Wolfgang, Klein, Christian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8425689/
https://www.ncbi.nlm.nih.gov/pubmed/34491877
http://dx.doi.org/10.1080/19420862.2021.1967714

Ejemplares similares